Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lineage Cell Therapeutics, Inc. (LCTX : AMEX)

• Company Description    Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are in clinical stage. Lineage Cell Therapeutics Inc., formerly known as BioTime Inc., is based in Carlsbad, California. Number of Employees: 77

• Price / Volume Information    Yesterday's Closing Price: $1.67 Daily Weekly Monthly 20 Day Moving Average: 1,081,469 shares Shares Outstanding: 230.33 (millions) Market Capitalization: $384.65 (millions) Beta: 1.74 52 Week High: $2.09 52 Week Low: $0.37 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.02% -3.86% 12 Week -4.57% -6.11% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2173 SALK AVENUE SUITE 200 - CARLSBAD,CA 92008 USA ph: 442-287-8990 fax: 510-521-3389 ir@lineagecell.com https://lineagecell.com

• General Corporate Information    Officers Brian M. Culley - Chief Executive Officer and Director Jill Ann Howe - Chief Financial Officer Deborah Andrews - Director Dipti Amin - Director Don M. Bailey - Director Peer Information Lineage Cell Therapeutics, Inc. (CORR.) Lineage Cell Therapeutics, Inc. (RSPI) Lineage Cell Therapeutics, Inc. (CGXP) Lineage Cell Therapeutics, Inc. (BGEN) Lineage Cell Therapeutics, Inc. (GTBP) Lineage Cell Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 53566P109 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/09/26 Share - Related Items Shares Outstanding: 230.33 Most Recent Split Date: 10.00 (3.00:1) Beta: 1.74 Market Capitalization: $384.65 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.03 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 18.34 Price/Cash Flow: - Price / Sales: 35.56 EPS Growth vs. Year Ago Period: -550.00% vs. Previous Quarter: -1,200.00% Sales Growth vs. Year Ago Period: -2.59% vs. Previous Quarter: 33.13% ROE 12/31/25 - - 09/30/25 - -72.02 06/30/25 - -20.00 ROA 12/31/25 - - 09/30/25 - -39.54 06/30/25 - -12.93 Current Ratio 12/31/25 - - 09/30/25 - 4.50 06/30/25 - 4.08 Quick Ratio 12/31/25 - - 09/30/25 - 4.50 06/30/25 - 4.08 Operating Margin 12/31/25 - - 09/30/25 - -370.53 06/30/25 - -122.14 Net Margin 12/31/25 - - 09/30/25 - -625.53 06/30/25 - -374.84 Pre-Tax Margin 12/31/25 - - 09/30/25 - -624.16 06/30/25 - -373.45 Book Value 12/31/25 - - 09/30/25 - 0.09 06/30/25 - 0.21 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.19 06/30/25 - 0.10

Powered by Zacks Investment Research ©